南方财经8月20日电,记者获悉,阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞®(英文商品名:Ultomiris®,通用名:瑞利珠单抗注射液),已获得中国国家药品监督管理局(NMPA)批准,用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症(PNH)患者的治疗。PNH是一种慢性、进行性且危及生命的血液系统罕见疾病。该疾病好发于青壮年,77%的PNH患者在20-40岁发病。PNH的临床主要表现为...
Source Link南方财经8月20日电,记者获悉,阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞®(英文商品名:Ultomiris®,通用名:瑞利珠单抗注射液),已获得中国国家药品监督管理局(NMPA)批准,用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症(PNH)患者的治疗。PNH是一种慢性、进行性且危及生命的血液系统罕见疾病。该疾病好发于青壮年,77%的PNH患者在20-40岁发病。PNH的临床主要表现为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.